Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amylin Pharmaceuticals LLC    

AMYLIN PHARMACEUTICALS LLC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2012 | 01:54pm CEST

Amylin Pharmaceuticals Inc. (>> Amylin Pharmaceuticals, Inc.) and Eli Lilly & Co. (LLY) said the European Commission approved its type 2 diabetes treatment Byetta as an add-on therapy to basal insulin.

The drug makers said Byetta with titrated basal insulin improves glycemic control after meals, and common side effects include nausea, diarrhea, dizziness and headache.

Lilly and Amylin in November severed their nine-year-old partnership that was supposed to furnish a blockbuster treatment for diabetes but was instead plagued by disappointing sales, regulatory troubles and company disputes, The Wall Street Journal reported. Amylin agreed to pay $250 million to Lilly upfront and as much as $1.2 billion more from sales of a molecule called exenatide that lowers the blood sugar of diabetics. That molecule is in the drug Byetta.

Amylin on Friday said it will assume responsibility for exenatide-product commercialization outside of the U.S. on a market-by-market basis by the end of 2013. During the transition period, Amylin will work with Lilly on plans for markets outside the U.S.

Amylin and Lilly shares closed Thursday at $15.41 and $39.81, respectively. Both were inactive premarket.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected] 

Stocks mentioned in the article : Amylin Pharmaceuticals, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -0.14% 80.09 Delayed Quote.-6.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYLIN PHARMACEUTICALS LLC
2012AMYLIN PHARMACEUTICALS, INC. : Bristol-Myers Squibb and AstraZeneca Complete Exp..
PU
2012Eli Lilly To Record $1.26 Billion Benefit from Amylin
DJ
2012ASTRAZENECA : Bristol-Myers Squibb Completes Purchase of Amylin
DJ
2012Bristol-Myers Executive Charged With Insider Trading
DJ
2012Bristol-Myers Executive Charged With Insider Trading
DJ
2012Bristol-Myers Executive Charged With Insider Trading
DJ
2012Bristol-Myers executive charged with insider trading
RE
2012U.S. Charges Bristol-Myers Executive With Insider Trading
DJ
2012Bristol-Myers Pension Executive Robert Ramnarine Arrested for Alleged Insider..
DJ
2012CARL ICAHN : Icahn Sounds the Alarm on Forest Labs
DJ
More news
Chart AMYLIN PHARMACEUTICALS LLC
Duration : Period :
Amylin Pharmaceuticals LLC Technical Analysis Chart | US0323461089 | 4-Traders
Sector and Competitors
1st jan.Capitalization (M$)
AMYLIN PHARMACEUTICALS LLC0
CSL LIMITED13.15%55 896
BIOGEN-17.44%55 645
ALEXION PHARMACEUTICALS-9.88%23 966
GRIFOLS-4.44%17 727
BIOMARIN PHARMACEUTICAL-7.70%14 491